Metacrine Inc

Metacrine Inc

MTCR - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$24.75M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Metacrine IncMetacrine Inc-0.4--106%-0.4

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$24.75 Million
Enterprise Value$-14,214,084.00
Earnings per Share$-1.45
Beta-0.74
Outstanding Shares42,569,515

Return

Return on Equity-106.08%ROE
Return on Assets-71.44%
Return on Invested Capital-72.28%

Valuation & Multiples

P/E Ratio-0.4P/E Ratio
PEG0.57PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT1.07
Enterprise Value to Net Income0
Total Debt to Enterprise-0.35
Debt to Equity0.37Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Metacrine Inc

35 employees

Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizi...

Metacrine Insider Information FAQ

In the latest 13F quarter on Stockcircle, 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.